SCHEMBL448183

SCHEMBL448183

CC(Cl)c1nc(=O)[nH]c2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
KDM4E B2RXH2 6/20 0.50
HPGD P15428 4/20 0.50
HSD17B10 Q99714 4/20 0.50
TSHR P16473 1/20 0.50
APP P05067 2/20 0.43
ADORA3 P0DMS8 4/20 0.42
HAVCR2 Q8TDQ0 1/20 0.41
LMNA P02545 2/20 0.41
GAA P10253 2/20 0.41
HTT P42858 2/20 0.41
GLA P06280 1/20 0.41
ATM Q13315 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CASP1 P29466 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CYP1A2 P05177 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28022676 0.86 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL3139711 0.73 KDM4E (0.58) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL30293081 0.73 ALDH1A1 (0.58) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL530191 0.73 ALDH1A1 (0.58) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL30095710 0.72 ALDH1A1 (0.53) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL28023268 0.72 ALDH1A1 (0.51) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL28203168 0.70 ALDH1A1 (0.46) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL28329925 0.70 ALDH1A1 (0.46) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL554709 0.69 KDM4E (0.58) ALDH1A1KDM4EHPGDHSD17B10TSHR
SCHEMBL4413903 0.69 KDM4E (0.58) ALDH1A1KDM4EHPGDHSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748440-B2 Quinazolinone modulators of nuclear receptors EXELIXIS, INC. (US) 2014-06-10 US disclosed
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2012-03-15 US disclosed
EP-1521746-B1 QUINAZOLINONE MODULATORS OF NUCLEAR RECEPTORS X CEPTOR THERAPEUTICS INC (US) 2011-04-27 EP disclosed
US-20080070864-A1 Quinazolinone Modulators Of Nuclear Receptors X-CEPTOR THERAPEUTICS, INC. (US) 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120064025-A1 Quinazolinone Modulators Of Nuclear Receptors NR1H4, NR1H2, NR1H3 ALDH1A1 3161/4885KDM4E 3717/4885HPGD 729/4885
US-20080070864-A1 Quinazolinone Modulators Of Nuclear Receptors NR1H4, NR1H2, NR1H3 ALDH1A1 3161/4885KDM4E 3717/4885HPGD 729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.